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Background: Between 30 and 50% of patients with major depressive disorder (MDD) do
not respond sufficiently to antidepressant regimens. The conventional pharmacological
treatments predominantly target serotonergic brain signaling but better tools to predict
treatment response and identify relevant subgroups of MDD are needed to support
individualized and mechanistically targeted treatment strategies. The aim of this study is to
invest igate ant idepressant-free pat ients with MDD using neuroimaging,
electrophysiological, molecular, cognitive, and clinical examinations and evaluate their
ability to predict clinical response to SSRI treatment as individual or combined predictors.
Methods: We will include 100 untreated patients with moderate to severe depression
(>17 on the Hamilton Depression Rating Scale 17) in a non-randomized open clinical trial.
We will collect data from serotonin 4 receptor positron emission tomography (PET) brain
scans, functional magnetic resonance imaging (fMRI), electroencephalogram (EEG),
cognitive tests, psychometry, and peripheral biomarkers, before (at baseline), during,
and after 12 weeks of standard antidepressant treatment. Patients will be treated with
escitalopram, and in case of non-response at week 4 or intolerable side effects, offered to
switch to a second line treatment with duloxetine. Our primary outcome (treatmentg July 2020 | Volume 11 | Article 6411
Abbreviations: MDD, Major Depressive D
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transporter; PET, Positron emission tom
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Frontiers in Psychiatry | www.frontiersin.orresponse) is assessed using the Hamilton depression rating subscale 6-item scores at
week 8, compared to baseline. In a subset of the patients (n = ~40), we will re-assess the
neurobiological response (using PET, fMRI, and EEG) 8 weeks after initiated
pharmacological antidepressant treatment, to map neurobiological signatures of
treatment responses. Data from matched controls will either be collected or is already
available from other cohorts.
Discussion: The extensive investigational program with follow-up in this large cohort of
participants provides a unique possibility to (a) uncover potential biomarkers for
antidepressant treatment response, (b) apply the findings for future stratification of
MDD, (c) advance the understanding of pathophysiological underpinnings of MDD, and
(d) uncover how putative biomarkers change in response to 8 weeks of pharmacological
antidepressant treatment. Our data can pave the way for a precision medicine approach
for optimized treatment of MDD and also provides a resource for future research and data
sharing.
Clinical Trial Registration: The study was registered at clinicaltrials.gov prior to initiation
(NCT02869035; 08.16.2016, URL: https://clinicaltrials.gov/ct2/results?cond=&term=
NCT02869035&cntry=&state=&city=&dist=)Keywords: major depressive disorder, biomarker, treatment response, serotonin 4 receptor, positron emission
tomography, functional magnetic resonance imaging, electroencephalogram, cognitionINTRODUCTION
Major Depressive Disorder (MDD) is one of the most severe and
common brain disorders worldwide with a huge impact on life
quality and socioeconomic status (1, 2). It has been linked to
serotonergic dysfunction, cognitive disturbances, brain network
dysfunction, vulnerability to stress, neuro-inflammation, and
gene by environment factors. Still, the understanding of the
pathogenesis remains limited. Guidelines for MDD treatment
selection are still predominantly based on simple clinical
observations about overall MDD severity, and in the case of
recurrent depressive episodes, it is also based on personal patient
history of treatment responses. Conventional medical treatment
is mainly based on intervention of the monoaminergic system in
the brain, in particular the serotonin (5-HT) system. Selective
serotonin reuptake inhibitors (SSRIs) act through blockage
and subsequent downregulation of the serotonin transporter
(SERT) (3), which presumably induces increased extracellular
5-HT levels. However, robust evidence for a central 5-HT
hypofunction in patients with MDD in vivo is lacking (4).
Roughly one third of patients suffering from MDD do not
respond sufficiently to 5-HT acting drugs (5, 6), suggesting aisorder; 5-HT: 5-hydroxytryptamine
euptake inhibitor; SERT, Serotonin
ography; fMRI, Functional magnetic
gram; 5-HT4R, Serotonin 4 receptor;
resonance imaging; ERP, Event-related
of auditory evoked potentials; CAR,
Hypothalamic-pituitary-adrenal axis;
on Rating Scale; HAMD6, 6-item
g 2diverse pathophysiology. The diagnostic criteria for MDD may
cover a heterogenous collection of various biological entities and
consequently, it is not surprising that a “one size fits all”
treatment strategy is suboptimal (7). Currently, the time from
starting to administer a potentially efficacious drug until it can be
determined if the clinical response is satisfactory is, at best, 4–6
weeks. In clinical practice, the lack of convenient and accurate
tools (e.g., quantitative and/or biological) to predict treatment
response prolongs the delay from diagnosis to effective treatment
and constitutes a major challenge for both clinicians and
patients. Therefore, stratification of subtypes and a shift toward
precision medicine, e.g., through identification of predictors of
treatment response, so-called biomarker(s) that can help
optimize treatment choice, is of paramount importance.
Candidate biomarkers could be related to neurotransmission,
specific neural networks or structural alterations in specific brain
regions that can be detected by brain imaging modalities such as
positron emission tomography (PET), functional magnetic
resonance imaging (fMRI), and electroencephalogram (EEG)
or altered biophysiological or cognitive functions (4, 8). It has
also been suggested that rather than a single biomarker, an
algorithm involving a set of biomarkers may prove useful to
subgroup patients and predict their response to certain treatment
strategies in MDD (9). Several biomarkers derived from prior
large studies such as iSPOT-D, EMBARC, and CANBIND for
prediction of drug response in MDD have been proposed (10–
12). Here, we use multimodalities (PET, fMRI, and EEG,
cognitive testing, psychometrics, and peripheral biomarkers) as
part of a deep phenotyping and as a unique feature to our trial,
we study modes of action in the brain on a neurotransmitter
level. Thus, our trial contributes with novel insights as well asJuly 2020 | Volume 11 | Article 641
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predictors of psychopharmacological antidepressant treatment
response. In a non-randomized, longitudinal, open clinical trial,
patients with moderate to severe depression will be treated with
SSRI following Danish guidelines. In order to map neurobiological
signatures of treatment, we will re-examine a subset of the cohort
with neuroimaging and EEG after 8 weeks of SSRI treatment and
assess cognitive changes after 12 weeks. This clinical trial is part of
a larger research initiative, “NeuroPharm”, which addresses
pertinent and basic questions regarding human brain disease
mechanisms and seeks to predict brain responses to categories
of neuro-modulatory interventions as well as treatment efficacy
(www.np.nru.dk). We anticipate that this study will critically
advance and inform future stratification strategies, further
uncover pathophysiological and treatment mechanisms and,
hopefully, guide future precision medicine approaches to
optimize treatment strategies for patients suffering from MDD.
Imaging techniques have vastly increased our understanding
of the underpinning cerebral mechanisms involved in MDD
(13). Serotonergic dysfunction is considered a central
mechanism in depression, and a recent review points at the 5-
HT 4 receptor (5-HT4R) as highly implicated in MDD (14). For
example, 5-HT4R agonism has shown rapid antidepressant -like
behavioral effects in rodents (15), and experimental models
suggest that cerebral 5-HT4R levels are sensitive to central 5-
HT modulation in rodents (16, 17). Subsequent clinical studies
from our group demonstrated that cerebral 5-HT levels can be
indexed in an inverse manner through molecular brain imaging
of the 5-HT4R by using the PET-ligand 11C-SB207145 in vivo
(18). We here aim to evaluate 5-HT4R binding as a candidate
predictor of antidepressant response to drugs targeting the 5-HT
system in the hitherto largest cohort of MDD patients with PET
brain imaging of serotonergic markers. We hypothesize that 1)
patients with MDD differ in cerebral [11C]SB207145 binding at
baseline compared to healthy controls; 2) [11C]SB207145 binding
at baseline in patients with MDD predicts remission after 8
weeks of pharmacological serotonergic intervention; 3) After 8
weeks of serotonergic intervention, patients with remitter status
have a significantly greater reduction in cerebral [11C]SB207145
binding than non-responders. For an overview of primary
hypotheses for other modalities, see Appendix 1.
fMRI can be used to assess regional activity and resting state
functional networks in MDD. One systematic review found
abnormal (negative bias) reactivity in amygdala responsiveness to
facial expressions and emotional stimulation in patients with MDD
versus healthy controls (19), and pre-treatment low amygdala
reactivity has shown to be predictive for antidepressant treatment
response (20). A study with 70 patients with MDD was able to
predict treatment recovery with ~80%, by investigating amygdala
reactivity to facial emotions and its interaction with history of early
life stress (21). Another study from our group showed that
amygdala reactivity was associated with brain 5-HT4R binding
and hence putatively extra synaptic 5-HT levels in healthy
individuals. This established a plausible connection between 5-HT
levels and amygdala activation, both involved in emotional cognitive
processes (22). This exemplifies how a multimodal PET and fMRIFrontiers in Psychiatry | www.frontiersin.org 3strategy can highlight molecular mechanisms mediating drug effects
on brain function (23). Resting state fMRI (rs-fMRI) measures
fluctuations in fMRI signal during the absence of an explicit task
and is widely used to assess distributed intrinsic networks such as
the “default mode network” (24). Alterations in rs-fMRI
connectivity have been described in MDD (25) and a recent study
suggested that rs-fMRI can define subtypes of MDD and predict
antidepressant treatment response (26), but this has been contested
by others (27). Although promising, brain imaging studies have in
general been inconclusive and with small sample sizes (9, 28). In the
current trial, we will use task-based and rs-fMRI in a large cohort of
patients withMDD and investigate the association between 5-HT4R
levels (as a proxy for brain serotonin levels) and the clinical outcome
of SSRI treatment.
EEG, a monitoring technique for direct ongoing neural
activity, has been reported to be associated with treatment
response in MDD [see, e.g., review (29)]. Prior studies have
found that treatment responders have higher cortical alpha
activity (30) and higher theta activity at rostral anterior
cingulate cortex compared to treatment non-responders (31,
32). Of note, these biomarkers were derived from the resting
EEG data, which is relatively easy to implement in the clinic.
Furthermore, earlier evidence from event-related-potential
(ERP) studies have suggested that ERP biomarkers such as
auditory P300 (a positive waveform around 300 ms after
stimulus onset) and loudness-dependence of auditory evoked
potentials (LDAEP) can be predict drug treatment response (33,
34), and are linked to the serotonergic transmitter system (35). In
the current trial, the predictive values of pretreatment EEG/ERP
biomarkers will be examined.
Disturbances in cognitive processes including memory,
attention, and executive functions are commonly reported in
MDD (36) and contribute to psychosocial impairment and
workforce disability (37). In addition, affective bias in information
processing (i.e., favoring negative information over positive
information at different levels of information processing) has been
proposed as a central mechanism in the development and
maintenance of depressive symptoms (38) which is also predictive
of later treatment response to antidepressant drugs (39). Notably,
cognitive disturbances do not always resolve with the remission of a
depressive episode, suggesting a dissociation between core mood
and cognitive symptoms in MDD (40). Combined with the low cost
and relative ease of testing in a clinical setting, this distinguishes
cognitive disturbances as a promising marker for stratification of
depression subtypes as well as an important target for
antidepressant treatment. In the present study, we therefore aim
to map a broad range of cognitive disturbances in MDD, including
both cold (non-emotional) and hot (emotional) cognitive processes,
and explore whether they may be used to characterize clinically
relevant subgroups in MDD. Based on earlier observations in
healthy individuals, we expect memory performance to map onto
hippocampal 5-HT4R availability (41) and possibly affective bias in
verbal memory in MDD (42).
Evidence of inflammation-associated MDD has emerged over
the years (43). Patients with MDD show elevated levels of
inflammatory markers in peripheral blood (44) which mayJuly 2020 | Volume 11 | Article 641
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with worse response (45). It has also been suggested that patients
with MDD have higher levels of activated microglia, as
illuminated with PET (46). Proinflammatory cytokines may
influence the 5-HT homeostasis in the brain by acutely
upregulate SERT through intercellular pathways (i.e., linked to
p38 mitogen-activated protein kinase) and presumably thereby
reduce synaptic 5-HT levels (47). Interestingly, cognitive
dysfunction, a prevalent symptom in depression, also appear to
be linked to an inflammatory response (48). We here aim to
determine if higher levels of systemic inflammatory markers are
associated with 5-HT4R brain binding, depression status at
baseline and clinical treatment response.
Another area of interest is the association between MDD and
signatures of early aging. There is an increased mortality and
prevalence of age-related diseases in recurrent depression (49, 50).
Oxidative stress on nucleic acids is a general element of aging and
has been suggested to be an underlying biological mechanism of
the accelerated aging observed in depression (51). Previous
research from our group has found evidence for such a link,
both in studies of psychological/biological stress and oxidative
stress in patients and in rodent models of depression (52–54).
Earlier findings indicate alterations in levels of oxidative stress
during antidepressant treatment and it is hypothesized that
treatment response is related to a transient increase in oxidative
stress levels, perhaps due to neurotrophic processes and/or
peripheral changes in energy metabolism (55–57). Urinary 8-
oxodG and 8-oxoGuo are sensitive and specific markers for
systemic DNA/RNA damage from oxidation (58). We here aim
to investigate urinary 8-oxodG and 8-oxoGuo as a predictive
biomarker for antidepressant treatment response, its association
with changes in psychopathology, structural and functional brain
changes, and markers of psychological and biological stress.
Additionally, we will investigate whether hormonal [estradiol,
testosterone, progesterone and follicle-stimulating hormone (in
females)] and metabolic status can predict antidepressant
treatment response and explore whether these associations are
related to genetic make-up (specified below), psychopathology and
the occurrence of early life stress using self-reported childhood
adverse events and parental bonding quality questionnaires, which
also may interact with the 5-HT system (59, 60).
Sexual dysfunction (e.g., low sexual desire, arousal difficulties,
and anorgasmia) is a prominent feature of MDD, which often
leads to a decline in quality of life (61, 62). Lack of interest to
what is usually pleasurable, i.e., anhedonia, is a core symptom in
MDD and may also be reflected in reduced sexual desire/interest.
Sexual dysfunction, in particular anorgasmia and sexual arousal
difficulties may further be linked to serotonergic dysfunctions
(63) as seen in MDD. As a complicating factor, impaired sexual
health related to MDD may worsen with antidepressant
treatments targeting the 5-HT system. For example, in a group
of 704 patients with MDD treated with an antidepressant drug
(SSRI) or serotonin-norepinephrine reuptake inhibitor, about
half of them developed or experienced worsening in their
decreased sexual desire as a side-effect, which was alsoFrontiers in Psychiatry | www.frontiersin.org 4associated with reduced quality of life, lower self-esteem
and adverse effects on mood and partner relations (62). We
currently do not know which patient characteristics predict
sexual dysfunction in response to SSRI treatment. However,
differences in individual serotonergic brain architecture and/or
serotonergic response to antidepressant treatment (e.g., SSRI)
may play a role. In this study, we aim to map the frequency and
predictors of SSRI induced sexual dysfunction and determine if
serotonergic tonus (measured by 5-HT4R PET binding) pre-
treatment, or changes in response to SRRI treatment, is
associated with sexual desire and/or development of SSRI-
induced sexual dysfunction in MDD.
Previous findings from our group have repeatedly demonstrated
a coupling between key features of the 5-HT system and
hypothalamus- pituitary- adrenal axis (HPA-axis), which regulates
the release of the stress-hormone cortisol (64). Such HPA-axis
dynamics can be measured by the cortisol awakening response.
Our results support that both serotonin transporter availability (65),
and serotonergic tone or direct capacity for 5-HT4R agonism
(64) support a healthy cortisol response to HPA-axis stimuli. A
well-functioning and dynamic HPA-axis is critical for coping with
everyday life stressors, and HPA-axis dysregulation is a prominent
feature of MDD. Although heightened CAR is associated with
relapse of depressive episodes in patients with a history of
depression (66), in the more advanced depressed stages, i.e.,
chronic depression, HPA-axis dynamics are blunted as opposed
to recent-onset depression (67). Notably, normalization of the
HPA-axis in response to SSRI treatment appears to protect
against relapse (68). Thus, the SSRI treatment response is likely to
depend on restoring HPA-axis dynamics at least in a subgroup of
MDD patients. In this trial, we will assess CAR in patients with
MDD, the effect of SSRIs on CAR, investigate its association with
baseline 5-HT4R distribution, as well as evaluate CAR as a predictor
of antidepressant treatment outcome.MATERIALS AND METHODS
Figure 1 shows a flowchart of the scheduled data collection over
the 12 weeks of pharmacological drug treatment of patients with
MDD. Healthy controls (HC) will be recruited as specified below.
Patients will be examined before (at baseline; week 0) and after 1,
2, 4, 8 and 12 weeks of SSRI treatment has been initiated.
Depression-severity will be monitored by the Hamilton
Depression Rating scale 17 items (HAMD17) and its subscale
of 6 items (HAMD6) (69). A subset of patients will be offered re-
examination with PET, fMRI, and EEG after 8 weeks of
treatment, to assess changes from baseline and its association
to treatment response. Patients from the whole spectrum of
treatment responses (from poor to excellent) will be invited in a
continuous fashion for this part of the study until allotted re-
examinations are completed. All patients will also repeat
cognitive testing at week 12. The power analysis in preparation
of the study was primarily anchored to the PET modality. We
estimated that we needed to include 100 patients to reach aJuly 2020 | Volume 11 | Article 641
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treatment response (binary classification, i.e., remitters vs non-
responders, see response-definition below) and baseline 5-HT4R
non-displaceable binding potential (BPND). These calculations
were based on an expected 20% maximum drop-out, ~50%
remission rate after 8 weeks of treatment (5, 6) and an expected
difference of 8% in 5-HT4R binding between remitters and non-
responders, corresponding to the previously found effect sizes on
5-HT4R change in BPND after fluoxetine treatment (18).
Calculations were further based on an average BPND of 0.71 and
a standard deviation of 0.073 (18, 70). With a rescan subgroup of
approximately 40 patients, and a Gaussian distribution of change
in BPND with an SD of 0.08 (log scale), we had an expected power
of 80% to identify a significant association between longitudinal
changes in BPND and changes in HAMD6 (i.e., secondary clinical
outcome, continuous scale).
Participants
Patients are recruited from a central referral center within the
mental health services in the Capital region of Denmark or directly
referred from one of five general practitioners in collaborations
with the study group (see Figure 2 (CONSORT) for details). Data
from healthy controls for the purpose of baseline comparisons to
patients with MDD are available from a pre-existing database on
site (71). The healthy control reference population will be
supplemented with newly recruited healthy controls from a local
volunteer database (www.nru.dk), as necessary.Frontiers in Psychiatry | www.frontiersin.org 5Inclusion Criteria for Patients
Patients between 18 and 65 years of age with a moderate to
severe, single, or recurrent episode of MDD consistent with the
Diagnostic and Statistical Manual of Mental Disorders -5 (DSM-
5) and International Statistical Classification of Diseases and
Related Health Problems -10 (ICD-10) criteria will be recruited
by a trained clinician. Inclusion requires a total score of >17 on
HAMD17 at baseline and the diagnose is confirmed by using the
diagnostic tool Mini International Neuropsychiatric Interview
(72). In addition, all patients are diagnostically verified by a
specialist in psychiatry before final inclusion.
Exclusion Criteria for Patients
Patients with a duration of their present depressive episode
exceeding two years are not included. No more than one
antidepressant treatment attempt in the current episode prior to
inclusion is allowed and only patients with no antidepressant
medication within the last two months are eligible. Patients with
known contraindications or previous non-response to an SSRI drug
after an adequate trial as well as a prior or present history of other
primary axis I psychiatric disorders are not included, i.e., MDD
must be the primary diagnosis. Other exclusion criteria are: severe
somatic illness; substance or alcohol use disorder; insufficient
language skills to undergo clinical assessments; acute suicidal
ideation or psychosis; patients who are deemed by a psychiatrist
to require other forms of antidepressant treatments; pregnancy or
breast feeding; use of any CNS drug that cannot be washed out priorFIGURE 1 | Flowchart of study trial assessments for patients with MDD.July 2020 | Volume 11 | Article 641
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migraine medicine, clonidine); medical conditions interfering with
measurements, contraindications for PET and/or MRI scans;
exposure to radioactivity >10 mSv within the last year; severe
sensory or intellectual impediments interfering with comprehension
of procedures or assessments and lastly any history of brain injury
(i.e., loss of consciousness and amnesia or symptoms of
concussion disorder).
Inclusion and Exclusion Criteria for Healthy Controls
Enrolled HC will be sought to match the patient population by
gender and age distribution. All HC will be screened for MDD
using a self-reporting questionnaire (major depressionFrontiers in Psychiatry | www.frontiersin.org 6inventory) (73). The HC meet the same inclusion and
exclusion criteria as required for patients apart from psychiatry
related issues (e.g., no current or history of mental illness or
unstable somatic condition).
Treatment and Investigation Program
Baseline Assessments Before Treatment
Each patient will receive a basic physical screening including somatic
status, routine blood samples, electrocardiogram including QTc
interval and collection of toxicology urine tests [The Rapid
ResponseTM Multi-Drug Test Panel (Urine)] for detection of drug
abuse within the last month. Women are screened for pregnancy
through self-reported use of contraceptives and a pregnancy urinaryFIGURE 2 | Flow diagram (CONSORT) of the NeuroPharm trial.July 2020 | Volume 11 | Article 641
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assessments of brain imaging with 11C-SB207145 PET and fMRI;
EEG-examination; cognitive testing, collection of questionnaires and
biologicalmaterial(venousblood,urine,andsaliva)asspecifiedbelow.
All HCwill receive corresponding baseline assessments.
Clinical Procedure After Treatment Initiation
After completion of baseline examinations, patients will receive
flexible doses of the SSRI drug escitalopram, initially 5 mg for 3–5
days depending on side effects (e.g., nausea), followed by 10 mg
daily until their first follow-up visit and further adjusted individually
to a maximum dose of 20 mg. Escitalopram was chosen as it binds
with high selectivity to the 5-HT transporter and has minimal
affinity for other receptors (74). Patients are allowed short-time
treatment with cyclopyrrolone (a nonbenzodiazepine hypnotic
agent) or oxazepam (a benzodiazepine) to reduce anxiety and
sleep disturbances which may be prominent in the initial
treatment phase and have shown not to influence treatment
continuation (75), but all are requested to avoid use 3 days prior
to brain scans. Clinical follow-up sessions with a study physician or
trained research assistant are scheduled in an out-patient clinical
setting after 1, 2, 4, 8 and 12 weeks of treatment to evaluate
treatment response and side effects. Visits can deviate a
maximum of one week from the original time scheduled. No
cognitive behavioral therapy or other psychotherapy program is
provided during clinical visits. No treatment (pharmacological or
psychotherapeutically) other than the medical monotherapy
provided in this study is allowed elsewhere during the trial. At
week 4, early non-responders (see definition below) or patients with
unacceptable side effects are offered to switch to a standard second
line antidepressant treatment; duloxetine (individually adjusted
doses of 30–120 mg per day), which is a serotonin-
norepinephrine reuptake inhibitor. Duloxetine was chosen
according to clinical guidelines for second line antidepressant
treatments. Cerebral 5-HT4R binding in humans is unaltered by
injection of escitalopram (76). No prior in vivo studies have
investigated the effect of duloxetine on 5-HT4R binding in the
human brain, but in vitro work has shown that duloxetine has
negligible affinity for the 5-HT4R (77). That is, none of the
pharmacological compounds directly target 5-HT4R’s. The week 4
timepoint is in line with national guidelines in Denmark for
switching to a second-line antidepressant treatment (4–6 weeks).
Since our cohort receives frequent clinical follow-up sessions,
patients can reach max dose of escitalopram (20 mg daily)
already after 2 weeks. As such, switching after 4 weeks is
considered appropriate for early non-responders in this trial set-
up. All antidepressant medicine will be provided for free to improve
compliance. Compliance will be assessed by serum escitalopram/
duloxetine blood tests after eight weeks of treatment as well as tablet
count at each follow-up. At each visit, depressive symptoms are
rated using the HAMD17 and the HAMD6 subscale. HAMD6
captures core symptoms of depression more directly (and
disregards sleeping quality), and has been found to be sensitive to
antidepressant treatment response (69). Potential side effects due to
intervention will be monitored at each visit using the “Udvalg forFrontiers in Psychiatry | www.frontiersin.org 7Kliniske Undersøgelser” scale (78). To ensure agreement and allow
alignment of ratings, HAMD17/HAMD6 co-ratings between all the
clinical investigators will be performed regularly during data
collection. A maximum of 20% deviation from the “gold-
standard” chief psychiatrist is allowed, or else a new satisfactory
co-rating is needed before independent rating of study participants.
Clinical Response Status
Primary Clinical Outcome Measure. The primary outcome
measure is categorical and built to capture patients with an early
as well as sustained, either excellent or poor response to treat-
ment. Patients are classified as either “remitters”, “non-
responders”, or “intermediate responders” after 8 weeks of
treatment. These categories are based on percentage changes of
depressive symptoms from baseline, as measured by HAMD6.
Remitters must have ≥50% reduction in HAMD6 at 4 weeks
(early responders) and a HAMD6 score <5 after 8 weeks of
treatment. Non-responders have <25% reduction in HAMD6
after 4 weeks (early non-responder) and <50% reduction in
HAMD6 after 8 weeks of treatment. Patients who do not meet the
criteria above are defined as “intermediate responders” at week 8.
The primary predictor analyses are directed to predict treatment
response in a binary fashion (either remitter or non-responder
(see Figure 3).
Secondary Clinical Outcome Measure. As a secondary out-
come, we use a continuous response measure, i.e., HAMD6
changes from baseline at week 8 divided by HAMD6 at baseline,
to allow analyses of the association between antidepressant
treatment response and baseline characteristics or treatment-
induced changes in the neurobiological modalities of interest.
Examination Modalities
PET Imaging and Quantification of
5-HT4R Brain Binding
PET scans are conducted using a high-resolution research
tomography Siemens PET scanner (CTI/Siemens, Knoxville,
TN, USA) (256 × 256 × 207 voxels; 1.22 × 1.22 × 1.22 mm).
Participants are positioned uniformly in spine position and a
specialized head holder is applied to reduce head motion during
the scan. All participants undergo a 6 min transmission scan and
are given an intravenous bolus of approximately 600 MBq of the
PET tracer ligand [11C]SB207145. The bolus is administered over
20 s followed by a 120-min dynamic PET data acquisition. The
radioligand is synthesized immediately prior to injection as
described elsewhere (79).
Preprocessing and PET Quantification
The 120 min dynamic PET acquisitions are reconstructed into 38
time frames (6 × 5 s, 10 × 15 s, 4 × 30 s, 5 × 2 min, 5 × 5 min, and
8 × 10 min) using a 3D-OSEM PSF algorithm (16 subsets and 10
iterations) (80) and TXTV-based attenuation correction (81).
For motion correction, the AIR 5.2.5 software will be used (82),
aligning each PET frame to the first 5-min frame. Structural 3-
Tesla MRI scans will be used for co-registration of the PETJuly 2020 | Volume 11 | Article 641
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carried out in a user-independent manner in PVElab software
(83) and mean tissue time activity curves for grey matter volumes
will be extracted for kinetic modeling. No partial volume
correction will be performed because of the high resolution of
the scanner. Regions of interest (ROI) have been chosen due to
their known relevance in mood disorders and abundance of 5-
HT4R density (84). The selected ROIs for the primary analyses
are neocortex, putamen, caudate nucleus and hippocampus. Co-
registration and correct ROI placement for all subjects will be
inspected in three planes by a trained investigator. PMOD
version 3.0 (PMOD, Zurich, Switzerland) will be used for
kinetic modeling and quantification of the 5-HT4R binding is
performed using non-displaceable binding potential (BPND) as
the final outcome measure. The simplified reference tissue model
will be used with cerebellum (excluding vermis) as reference
region which previously has been validated in humans (76).
BPND is defined as:
BPND =
fND  Bavail
KD
where fND is the tissue free fraction of non-protein bound
11C-
SB207145, Bavail is the concentration of available 5-HT4R and
KD is the dissociation constant for the tracer at equilibrium.
Thus, BPND is proportional to the density of 5-HT4R.
MRI and fMRI Imaging
All participants are screened for MR-compatibility and
thoroughly instructed how to perform the fMRI paradigms by
a trained study assistant who uses standardized instructions. All
MRI scans for patients will be acquired using the same Siemens
3-Tesla Prisma scanner with a 64-channel head coil. High-
resolution structural T1- and T2-weighted MR images will be
acquired. Blood oxygenation level dependent fMRI scans will be
obtained during a commonly used emotional faces paradigm (85,
86), reward-related guessing paradigm (87, 88) and a 10-min rs-Frontiers in Psychiatry | www.frontiersin.org 8fMRI scan. During the rs-fMRI scan, participants are asked to
close their eyes, let their mind wander and to not fall asleep. All
structural scans of patients will be screened for pathological
abnormalities by a medical specialist in radiology.
EEG
EEG data is recorded using a 256-channel HydroCel Sensor Net
system (EGI, Inc., Eugene, OR) at 1,000 Hz with 0.1–100 Hz
analog filtering where vertex electrode serve as the reference.
Impedances across all electrodes are kept below 50 kW. EEG/ERP
recording at baseline included: resting EEG (with eyes closed and
open), two-tone auditory oddball and the LDAEP tasks. The
same EEG/ERP recording will be re-tested in a subgroup of
patients after 8 weeks of treatment.
Resting EEG
Resting EEG is recorded during four 3-min periods with a
counterbalanced order of OCOC (O for eyes open, C for eyes
closed) or COCO between subjects. Participants are instructed to
remain still and relax, avoid eye-blinks and movements and to relax
chin muscles during recording. Absolute and relative powers are
computed using the following frequency bands: d (1–4 Hz), q (4–8
Hz), a (8–12 Hz), and beta (8–30 Hz). In addition, alpha peak
frequency (APF) is identified by the frequency at maximal absolute
power from the spectral range of 7–13 Hz. Frontal alpha asymmetry
will be calculated using alpha power with the formula of (F4 – F3)/
(F4 + F3) (Arns et al., 2015). Furthermore, theta activity will be
extracted from anterior cingulate cortex with exact low-resolution
electromagnetic tomography (eLoreta).
Task Elicited ERPs
The two-tone auditory oddball paradigm consists of two acoustic
stimuli with different frequencies. Participants are presented with a
series of standard tones (500 Hz) and deviant tones (1,000 Hz)
binaurally through inserted earphones (Etymotic Research Inc., ER
3C). They are instructed to press a button when the deviant tones
are presented while ignoring the standard tones. ERP componentsFIGURE 3 | Response categorization for patients with MDD after 4 and 8 weeks of antidepressant treatment based on changes in HAMD6 score.July 2020 | Volume 11 | Article 641
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amplitude (baseline to peak) will be extracted by the averaged
trials. Participants are presented with five acoustic stimuli with
different intensities (60, 70, 80, 90, and 100 dB SPL) in the same
frequency of 1,000 Hz. No response is needed. The primary
outcome is the slopes of peak-to-peak N1/P2 amplitudes
extracted from the average trials at each intensity. A more
comprehensive description of the EEG data will be presented in
the subsequent reports.
Cognitive Testing
All participants undergo cognitive testing using selected tasks
from the novel test battery EMOTICOM, assessing affective and
social cognition including emotional face recognition, emotional
threshold detection, theory of mind, and moral emotions (89). In
addition, affective memory (90), working memory, reaction time
and IQ will also be assessed. Testing is planned and conducted by
trained neuropsychologists prior to start of drug intervention
and again after 12 weeks of treatment.
Psychometrics
Apart from clinical visits including HAMD17/6 ratings, patients will
apply self-monitoring during the study period and fill out Danish
versions of online questionnaires throughout the study. All
questionnaires will be imported directly to an internal database
through LimeSurvey, a free and open source software. Before EEG
scans and cognitive testing, all participants will report their current
mood state using an in-house Likert-scale. An adjusted Likert-scale
will be filled out after eachMR-scan. During visits at week 4, week 8,
and week 12, patients are also asked to fill out a comprehensive set
of self-rating state questionnaires (see Table 1 for a full overview).
Healthy controls will be asked to fill out selected state questionnaires
as part of their baseline assessments.
Biomaterials
Blood
At baseline, all participants will be screened for basic somatic
status to exclude somatic conditions with possible influence on
depressive symptoms. Blood samples will be collected throughout
the study (see Table 2 for a full overview) for determination of
inflammatory status (high sensitivity C-reactive protein, tumor
necrosis factor-a, Interleukin-6, -18, and -10) (106–109);
epigenetic variations (SERT, FKBP Prolyl Isomerase 5, Catechol-
O-Methyltransferase (COMT), monoamine oxidase-A,
glucocorticoid-, estrogen-, oxytocin receptor and oxytocin gene-
methylation); extraction of DNA for genotypes of relevance
(rs41271330 (110), serotonin-transporter-linked polymorphic
region (5-HTTLPR) (70), COMT, Brain-Derived Neurotrophic
Factor val66met) and ABCB1, FZD7, and WNT2B (that
presumably influence responsiveness to pharmacological
antidepressant treatment (111)). At week 8, serum samples of
the antidepressant drug (i.e., escitalopram or duloxetine) are
collected as trough concentrations in steady state, with primary
purpose of monitoring compliance. The samples will be stored at
−20°C (or −80°C for plasma EDTA samples) until analyzation in
batches at completion of the trial. Quantification of escitalopram
and duloxetine in serum will be performed at the Laboratory of theFrontiers in Psychiatry | www.frontiersin.org 9Danish Epilepsy Centre, Filadelfia, using a routine UPLC-MS/MS
method developed in-house. Standard operating procedure
instructions have been established before trial initiation and will
be followed during the assessment of all biomaterial.
Saliva
Saliva will be collected to determine the total cortisol output across
one day as well as dynamics of the HPA-axis, as indexed by CAR.
Serial saliva samples will be sampled at home and collected at
baseline and at week 8 (see Table 2). Those visits will be placed as
close to the PET-scan day or week 8 visit as possible, and patients
are instructed to take samples immediately after awakening and
again after 15, 30, 45, and 60 min, at 12, 6, and 11 pm. Participants
are also instructed to collect saliva samples preferably during
weekdays, not perform strenuous exercise <2 h and not to have
any oral intake or brush their teeth <1 h prior to sampling. Cohen’s
Perceived Stress Scale and basic information about sleep and food
intake will be filled out in conjunction with the home-sampling. All
participants receive careful training in saliva collection, instructions
of home-sampling procedures; cold storage of samples and fast
delivery either by mail or personal delivery to the laboratory facility
for preparation. When received, salivary test-tubes are centrifuged
and stored at −80°C until later single-batch analysis.TABLE 1 | Table over questionnaires obtained throughout the study.
Questionnaires Time point
Baseline Week1 Week
2
Week
4
Week
8
Week
12
MINI X
HAMD-17/6 X X X X X X
UKU X X X X X
NEO-PIR X
CATS X
EHI X
OS-FHAM X
PBI-mother/
father
X
POMS* X X X
Likert-scale* X X X
BDI-II X X X X
MDI X X X X
PSS X X X X
SHAPS X X X X
RRS X X X X
CSFQ_F_C X X X X
SUSY item 32 X X X X
Activity X X X X
GAD-10 X X X XJuly 2020 | Volume 11 | ArticTrait questionnaires at baseline includes personality traits with NEO-PIR (91); Child Abuse
and Trauma Scale (CATS) (92) a survey about early life stress which has shown to be able
to modulate the serotonin system in the brain (93); handedness with Edinburgh
Handedness Inventory (EHI) (94); an in-house version of the Family History Assessment
module (FHAM) questionnaire, i.e., “Online Stimulant” (OS)-FHAM; Parental Bonding
Inventory (PBI) (both mother and father) (95). State conditions included a self-rating
questionnaire of Profile of Mood States (POMS) (96); an in-house Likert-scale; Beck’s
Depression Inventory-II (BDI-II) (97); Major Depression inventory (MDI) (98); Cohen’s
Perceived Stress Scale (PSS) (99, 100); Snaith-Hamilton Pleasure Scale (SHAPS) (101);
Rumination Response Scale (RSS) 102; Changes in Sexual Functioning Questionnaire
(CSFQ) (103); “Sundhed og Sygelighed” Sex Quality Questionnaire item 32 (SUSY-item
32) (104); an in-house questionnaire about daily physical activity (71); and Generalized
Anxiety Disorder-10 (GAD-10) (105). * Collected in immediate extension to EEG and MR
examinations or cognitive testing.le 641
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Spot-urine samples will be collected at baseline and week 8 visits
for patients (see Table 2) in 2-ml Eppendorf tubes and will be
stored at −20°C for later single-batch analysis. Apart from
pregnancy and drug-screening (see Baseline Assessments Before
Treatment), all urine samples will be analyzed for 8-oxodG and
8-oxoGuo markers for systemic DNA/RNA damage with ultra-
performance liquid chromatography with tandem mass
spectrometry and normalized to urinary creatinine (112).
Statistical Analyses
Evaluating Associations Between Baseline
Measures, Changes From Baseline Measures, and
Clinical Outcomes
Baseline data from each modality of interest, i.e., PET, EEG,
fMRI, MRI, cognitive measures, peripheral molecular markers,
and clinical/demographic patient profiles, will be available forFrontiers in Psychiatry | www.frontiersin.org 10evaluating associations with the clinical outcomes for the entire
group (n = 100 included). Changes from baseline data will be
available for the subgroup (around n = 40 invited), who will be
re-examined with brain scans and EEG for evaluating an
association between changed measures and clinical outcomes.
Similarly, cognitive follow-up data will be collected for all
patients after 12 weeks of treatment. Primary analyses will test
mean differences in baseline measures of the biomarkers from
each modality between healthy controls and patients as well as
response groups (remitter vs. non-responder at week 8, i.e.,
primary clinical outcome) using multiple linear regressions. This
analysis focuses on the two extreme outcome groups. Secondary
analyses will test the association between baseline measures of the
biomarkers from each modality and antidepressant treatment
response on a continuous scale, i.e., relative change in HAMD6,
using linear multiple regression. This analysis incorporates the full
spectrum of clinical outcomes. Similar analyses will be performed
to study the association between the change from baseline
measures of the biomarkers and the clinical outcomes.
Regression models will be adjusted for age and sex, as well as
modality-specific relevant covariates. For instance, 5-HTTLPR
status is predictive of 5-HT4R binding (70) and will be adjusted
for in the analyses concerning 5-HT4R. When relevant,
interactions will be evaluated, e.g., we will test if the association
between the clinical outcome and 5-HT4R is moderated by
inflammatory status. Diagnostic regression tools will be used to
assess model’s assumptions (e.g., linearity of the effects, normality
assumption for residuals). When violated, corrective procedures
will be used (e.g., splines and bootstrap resampling) (113). As
appropriate, adjustments for multiple comparisons will be
performed within each modality. In the analysis of the PET
data, we will instead use a Latent Variable Model relating the 5-
HT4R binding in several brain regions (neocortex, caudate
nucleus, putamen and hippocampus) to treatment outcome via
a latent variable (114). This allows us to assess the association
between 5-HT4R binding and clinical outcome with a single test.
Patients are considered with un-verified compliance if they have
taken less than 2/3 of their antidepressant medicine, missed their
week 8 visit, or have undetectable serum drug levels at week 8 (i.e.,
<10 nM for escitalopram and <15 nM for duloxetine). Patients
with un-verified compliance will not be included in primary
longitudinal analyses of treatment response. Missing data will
therefore be handled using complete case analysis which in
regression models is valid when the probability of dropping out
of the study is, conditional on the covariates, independent of the
outcome. If any participants were to be excluded during the study
because of their clinical outcome, a sensitivity analysis will
be performed.
Evaluation of the Predictive Value of the
Biomarkers Within Modality
Logistic regression models for the primary clinical outcome will be
used to obtain the probability of each patient to be a remitter (vs. a
non-responder) based on its clinical data and the value of a
modality-specific biomarker. Given a threshold (e.g., 0.5),TABLE 2 | Somatic status and biomaterial assessed at various timepoints
throughout the study.
Analysis Sample Timepoint
Baseline Week
8
Week
12
Somatic
blood-
sample
screening
Hemoglobin, white blood cell count,
metamyelo.+myelo.+promyelocytes.
C-reactive protein.
X X X
Na+, K+, Creatinine X
ASAT, ALAT, GGT, LDH, BAP X
Albumin, Coagulation factors II+VI+X,
thrombocytes
X
B12, Folate X
25-OH-vitamin D X
Blood sugar, HbA1c X
Triglycerides, total-cholesterol, HDL,
LDL
X
TSH, Ionized Calcium X
Estradiol, testosterone, progesterone,
FSH (females)
X
Somatic
examination
Electro Cardiogram (ECG)
Neurological status
Somatic status
X
X
X
Compliance
to medicine
control
S -escitalopram or S -duloxetine X
Biobank Inflammation and cytokines (hsCRP,
TNF-a, IL-6, IL-18 and IL-10)
X X X
Biobank Epigenetics
(5-HTT, glucocortocoid-, FKBP5,
COMT, MAO-A, estrogen-, oxytocin
receptor and oxytocin gene-
methylation)
X X X
Biobank Genotypes
(rs41271330, 5-HTTLPR, COMT,
BDNFval66met)
X
Biobank Gene transcription profiles
(mRNA and microRNA, ABCB1,
FZD7 and WNT2B)
X X X
Oxidative
stress
Urine (8-oxo-dG and 8-oxo-Guo) X X
Biobank Saliva (Cortisol awakening response) X XJuly 2020 | Volume 11 | Article 641
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will be predicted to be remitters, otherwise to be non-responders.
The receiver operating characteristic (ROC) curve will be used to
assess the compromise between sensitivity and specificity of this
classification across thresholds. Since a 33% remission rate is
expected in treatment regimen comparable to ours (5), we will
focus on the ROC curve with high-specificity. The AUC (area
under the curve) of the relevant part of the ROC curve will be
reported as a summary of the predictive performance of each
biomarker. The classification performance (accuracy, positive
predictive value, negative predictive value) at the threshold
optimizing the sum specificity and specificity will also be
reported. To limit optimistic biases, these measures will be
estimated using five-fold cross-validation (115). A permutation
procedure will be used to obtain the null distribution of the
predictive performance, against which the observed performance
will be compared. Additional classification schemes may be
considered (e.g., responder status as defined by ≥50% reduction
in HAMD6 at week 8), with appropriate adjustment for inflated
type-I error, to facilitate comparison of the current data with other
relevant clinical trials. The predictor performance will be evaluated
in a modality specific fashion and at a next stage, combined
predictors will be evaluated.
Predictive Value of the Biomarkers Across Modalities
Two strategies will be considered to optimize prediction of
treatment response using biomarkers measured at baseline
across modalities. In the first strategy, we will combine the
specific biomarker-candidates across all modalities (as
predefined in Appendix 1), which will generate around 50
candidate biomarkers. A dimension reduction step will be used
to define a small number of predictors (roughly 5–10) that will be
used in a logistic regression model. The second strategy will use
an algorithm to (i) identify, in a data-driven way, biomarkers
with a predictive value among all the existing biomarkers
(roughly 5,000–10,000) and (ii) predict treatment response
based on the identified subset of informative biomarkers. We
will investigate the use of machine learning methods (e.g.,
random forest, neural networks) as well as ensemble methods
[e.g., Super Learner (116)]. The assessment of the predictive
performance of these strategies will be carried out as described in
the previous section.Ethics Approval and Consent to
Participate
The study protocol complies with the Declaration of Helsinki II
and data collected during the trial will be monitored throughout
the study period (for every 10th patient included) by an
independent Good Clinical Practice unit in the capital region
of Denmark (www.gcp-enhed.dk/en). The study has been
approved by the Committees on Health Research Ethics in the
Capital Region of Denmark (reference number: H-15017713),
the Danish Data Protection Agency (04711/RH-2016-163), and
Danish Medicines Agency (protocol number: NeuroPharm-NP1,Frontiers in Psychiatry | www.frontiersin.org 11EudraCT-number 2016-001626-34). All potential participants
will receive oral and written information about the study by
the enrolling clinician, and all enrolled participants will provide
written informed consent prior to inclusion. Adverse events have
been scheduled to be reported annually to the Danish Medicines
Agency. The study was registered at clinicaltrials.gov prior to
initiation (NCT02869035), date: 08.16.2016.
Availability of Data and Materials
Data management and monitoring during the study agrees to the
rules on protection of personal data. To protect confidentiality,
paper-based material (e.g., cognitive test results) will be stored in a
secured archive, while electronical data files that are identifiable will
be stored in password secured files behind firewall in accordance to
regulations. To promote data quality, the primary outcome
measurement (HAMD17/6 scores) will be obtained during
interviews on paper, manually transferred into the local database
through LimeSurvey and cross-checked twice before used in
analyses. Biological material will be coded with a unique
identification-number and access to de-identification keys is
restricted to authorized personnel only and stored in a temporary
biobank located in secured areas in the laboratory facility. The
biomaterial will later be analyzed in batches to reduce noise, and
potential extra material after the end of the clinical trial will be
transferred to the CIMBI biobank (71). All biological material will
ultimately be anonymized after 15 years after the end of trial.
Progress to Date
The study opened for inclusion of patients in August 2016. To
date, the remaining biological data including genetic status of
healthy controls are planned to be collected. Obtained biological
material is currently being analyzed and processing of imaging
data is on-going. Results from the trial are planned to be
communicated to the participants and public through
publication in international medical journals.DISCUSSION
The main purpose of the present study is to identify individual
or combined predictors (biomarkers) of s tandard
pharmacological antidepressant treatment outcome in MDD,
by using multiple modalities such as brain imaging (PET,
fMRI), EEG, cognitive tools, and clinical and molecular
markers. Special emphasis in the study design has been given
to evaluate the biomarker 5-HT4R PET as a promising clinically
relevant tool since the 5HT4R availability is of interest in the
pathophysiology and as a therapeutic target in MDD, and also
as an index of serotonin tonus. The aim of this trial is not to
investigate the specific treatment efficacy but to investigate
biomarkers for response to standard treatment in a
naturalistic setting, e.g., similar to the STAR*D trial (117).
The study includes multiple cross-sectional and longitudinal
measures in a large number of patients and controls, whichJuly 2020 | Volume 11 | Article 641
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or clusters of biomarkers of treatment prediction, (b) apply
the findings for stratification of MDD, (c) advance the
understanding of pathophysiological underpinnings of MDD,
(d) map neurobiological signatures of antidepressant treatment
response, and lastly (e) to ideally pave a way for a precision
medicine approach for optimized treatment of MDD.ETHICS STATEMENT
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Kinetic Modeling of 11C-SB207145 Binding to 5-HT4 Receptors in the
Human Brain In Vivo. J Nucl Med (2009) 50(6):900–8. doi: 10.2967/
jnumed.108.058552
80. Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro MJ, Buvat I, et al. Impact
of Image-Space Resolution Modeling for Studies with the High-Resolution
Research Tomograph. J Nucl Med (2008) 49(6):1000–8. doi: 10.2967/
jnumed.107.045351
81. Keller SH, Svarer C, Sibomana M. Attenuation correction for the HRRT PET-
scanner using transmission scatter correction and total variation regularization.
IEEE Trans Med Imaging (2013) 32(9):1611–21. doi: 10.1109/TMI.2013.2261313
82. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for
aligning and reslicing pet images. J Comput Assist Tomogr (1992) 16
(4):620–33. doi: 10.1097/00004728-199207000-00024
83. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbøl S, Frøkjaer VG,
et al. MR-based automatic delineation of volumes of interest in human brain
PET images using probability maps. Neuroimage (2005) 24(4):969–79.
doi: 10.1016/j.neuroimage.2004.10.017
84. Madsen K, Marner L, Haahr M, Gillings N, Knudsen GM. Mass dose effects
and in vivo affinity in brain PET receptor studies - a study of cerebral 5-HT 4
receptor binding with [11C]SB207145. Nucl Med Biol (2011) 38(8):1085–91.
doi: 10.1016/j.nucmedbio.2011.04.006
85. da Cunha-Bang S, Fisher PM, Hjordt LV, Perfalk E, Persson Skibsted A,
Bock C, et al. Violent offenders respond to provocations with high amygdala
and striatal reactivity. Soc Cognit Affect Neurosci (2017) 12(5):802–10.
doi: 10.1093/scan/nsx006
86. Nikolova YS, Iruku SP, Lin C-W, Conley E D, Puralewski R, French B, et al.
FRAS1-related extracellular matrix 3 (FREM3) single-nucleotide
polymorphism effects on gene expression, amygdala reactivity and
perceptual processing speed: An accelerated aging pathway of depression
risk. Front Psychol (2015) 6:1377. doi: 10.3389/fpsyg.2015.01377
87. Forbes EE, Hariri AR, Martin SL, Silk JS, Moyles DL, Fisher PM, et al.
Altered striatal activation predicting real-world positive affect in adolescent
major depressive disorder. Am J Psychiatry (2009) 166(1):64–73.
doi: 10.1176/appi.ajp.2008.07081336
88. Nikolova YS, Ferrell RE, Manuck SB, Hariri AR. Multilocus genetic profile
for dopamine signaling predicts ventral striatum reactivity .
Neuropsychopharmacology (2011) 36(9):1940–7. doi: 10.1038/npp.2011.82July 2020 | Volume 11 | Article 641
Köhler-Forsberg et al. Predicting Treatment Outcome in MDD89. Bland AR, Roiser JP, Mehta MA, Schei T, Boland H, Campbell-Meiklejohn
DK, et al. EMOTICOM: A Neuropsychological Test Battery to Evaluate
Emotion, Motivation, Impulsivity, and Social Cognition. Front Behav
Neurosci (2016) 10:25. doi: 10.3389/fnbeh.2016.00025
90. Jensen CG, Hjordt LV, Stenbæk DS, Andersen E, Back SK, Lansner J, et al.
Development and psychometric validation of the verbal affective memory
test. Memory (2016) 24(9):1208–23. doi: 10.1080/09658211.2015.1087573
91. Costa P, McCrae R. (2008). The revised NEO personality inventory (NEO-PI-
R). The SAGE Handbook of Personality Theory and Assessment. 2:179–98.
doi: 10.4135/9781849200479.n9
92. Sanders B, Becker-Lausen E. The measurement of psychological
maltreatment: Early data on the child abuse and trauma scale. Child Abus
Negl (1995) 19(3):315–23. doi: 10.1016/S0145-2134(94)00131-6
93. Harrison EL, Baune BT. Modulation of early stress-induced neurobiological
changes: A review of behavioural and pharmacological interventions in
animal models. Transl Psychiatry (2014) 4(5):e390. doi: 10.1038/tp.2014.31
94. Oldfield RC. The assessment and analysis of handedness: The Edinburgh
inventory. Neuropsychologia (1971) 9(1):97–113. doi: 10.1016/0028-3932
(71)90067-4
95. Parker G, Tupling H. Brown LB. A Parental Bonding Instrument. Br J Med
Psychol (1979) 52:1–10. doi: 10.1111/j.2044-8341.1979.tb02487.x
96. McNair DM, Lorr M, Droppleman LF.Revised manual for the Profile of
Mood States. (San Diego, CA: Educational and Industrial Testing Services)
(1992).
97. Beck AT, Steer RA, Brown GK. Manual for the Beck depression inventory-II.
San Antonio TX Psychol Corp (1996) doi: 10.1037/t00742-000
98. Forsell Y. The Major Depression Inventory versus schedules for clinical
assessment in neuropsychiatry in a population sample. Soc Psychiatry
Psychiatr Epidemiol (2005) 40(3):209–13. doi: 10.1007/s00127-005-0876-3
99. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress.
J Health Soc Behav (1983) 24(4):385–96. doi: 10.2307/2136404
100. Cohen S, Williamson G. Perceived stress in a probability sample of the
United States. Soc Psychol Heal (1988) 31–67. doi: 10.1111/j.1559-
1816.1983.tb02325.x
101. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A
scale for the assessment of hedonic tone. The Snaith-Hamilton Pleasure
Scale. Br J Psychiatry (1995) 167(1):99–103. doi: 10.1192/bjp.167.1.99
102. Treynor W, Gonzalez R, Nolen-Hoeksema S. Rumination reconsidered: A
psychometric analysis. Cognit Ther Res (2003) 27:247–59. doi: 10.1023/
A:1023910315561
103. Clayton AH, McGarvey EL, Clavet GJ. The changes in sexual functioning
questionnaire (CSFQ): Development, reliability, and validity.
Psychopharmacol Bull (1997) 33(4):731–45.
104. Eplov L, Giraldi A, Davidsen M, Garde K, Kamper-Jørgensen F. Sexual desire
in a nationally representative danish population. J Sex Med (2007) 4(1):47–
56. doi: 10.1111/j.1743-6109.2006.00396.x
105. Bech P. Rating scales in depression: Limitations and pitfalls. Dialogues Clin
Neurosci (2006) 8(2):207–15.
106. Dahl J, Ormstad H, Aass HCD, Malt UF, Bendz LT, Sandvik L, et al. The
plasma levels of various cytokines are increased during ongoing depression
and are reduced to normal levels after recovery. Psychoneuroendocrinology
(2014) 45:77–86. doi: 10.1016/j.psyneuen.2014.03.019Frontiers in Psychiatry | www.frontiersin.org 15107. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A Meta-
Analysis of Cytokines in Major Depression. Biol Psychiatry (2010) 67(5):446–57.
doi: 10.1016/j.biopsych.2009.09.033
108. Howren MB, Lamkin DM, Suls J. Associations of depression with c-reactive
protein, IL-1, and IL-6: A meta-analysis. Psychosom Med (2009). 71(2):171–
86. doi: 10.1097/PSY.0b013e3181907c1b
109. Liu Y, Ho RCM, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha
(TNF-a) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients
with major depressive disorder: A meta-analysis and meta-regression. J Affect
Disord (2012). 139(3):230–9. doi: 10.1016/j.jad.2011.08.003
110. Tammiste A, Jiang T, Fischer K, Mägi R, Krjutsǩov K, Pettai K, et al. Whole-
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